

DATE:	2022 April 4
TO:	All Clinicians – Calgary Zone, All Acute Care Nursing Units, Calgary Zone
FROM:	Dr Etienne Mahe, Hematopathologist & Medical Informatics Lead, South Sector, APL
RE:	Changes to Anti Xa test codes in Calgary

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective April 12, 2022, clinician providers/prescribers must select one of four specific Anti Xa tests, choosing the most appropriate drug:

<u>Test Name</u>	<u>Test Mnemonic</u>
Anti Xa Unfractionated Heparin	Xa UFH
Anti Xa LMWH (Low Molecular Weight Heparin)	Xa LMWH
Anti Xa Apixaban	Xa APIX
Anti Xa Rivaroxaban	Xa RIV

- Patients not receiving treatment should be defaulted to Anti Xa Unfractionated Heparin (Xa-UFH). The laboratory will no longer be able to perform Anti Xa testing if a specific drug is not indicated (eg if testing is requested using a paper requisition, without indicating the specific drug).

Background

- Anti Xa testing can assist with the acute care/inpatient or intra-/post-operative monitoring of heparin-based therapies. Anti Xa testing is also occasionally used to monitor certain oral anticoagulant medications (ie Apixaban (Brand name: Eliquis) and Rivaroxaban (Brand name: Xarelto), when specifically clinically indicated.
- To facilitate STAT and 24-hour Anti Xa test availability, this testing will move from DSC Special Coagulation and will now be performed at the Foothills Medical Center, Hematology dept.
- Reagents for Anti Xa testing have been developed with specific sensitivity to heparin, LMWH, Apixaban, and Rivaroxaban. Selecting the appropriate drug is essential for accurate reporting of results.

How this will impact you

- The current Anti Xa (AFXA) order will no longer be available April 12, 2022.
- Order specific Anti Xa level based on a specified drug:

Anti Xa Unfractionated Heparin
 Anti Xa LMWH
 Anti Xa Apixaban
 Anti Xa Rivaroxaban



Action Required

- Order appropriate Anti Xa test code based on the appropriate drug.
- Test Directory will be updated to reflect changes for Anti Xa testing.

Effective April 12, 2022

Questions/Concerns

- Etienne Mahe, Hematopathologist & Medical Informatics Lead, South Sector
Etienne.mahe@albertaprecisionlabs.ca; 403-944-5290

Approved by

- Meer-Taher Shabani-Rad, MD, Section Chief, Hematopathology, South Sector, APL
- Paul Klonowski, MD, Associate Medical Director, South Sector, APL